<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903523</url>
  </required_header>
  <id_info>
    <org_study_id>970</org_study_id>
    <nct_id>NCT03903523</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Lumen Apposing Metal Stents</brief_title>
  <acronym>LAMS</acronym>
  <official_title>Efficacy and Safety of Lumen Apposing Metal Stents: a Retrospective Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasonography (EUS) has revolutioned the management of gastroenterological&#xD;
      patients and is acquiring an increasingly important role.&#xD;
&#xD;
      The development of specifically designed stents has significantly increased the technical and&#xD;
      clinical success rate of the EUS-guided procedures, considerably reducing the rate of adverse&#xD;
      events. Currently EUS has a prominent role in drainage of peripancreatic fluid collections&#xD;
      and it represents an important therapeutic option for patients with distal malignant biliary&#xD;
      obstruction, in which the ERCP fails, allowing the positioning of a transgastric or&#xD;
      transbulbar lumen apposing metal stent (LAMS) to drain the biliary duct. Moreover, the&#xD;
      EUS-guided gallbladder drainage of patients with high surgical risk and acute cholecystitis,&#xD;
      which cannot be operated, is another important therapeutic indication.&#xD;
&#xD;
      Our aim is to perform a multicentre retrospective analysis of all types of EUS drainage&#xD;
      (gallbladder drainage, biliary drainage, peripancreatic fluid collection drainage) with the&#xD;
      positioning of LAMS in order to evaluate the rate of technical and clinical success and to&#xD;
      assess the safety profile of these procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the rate of technical and clinical success of EUS drainage (gallbladder drainage, biliary drainage, peripancreatic fluid collection drainage) with the positioning of lumen apposing metal stents</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Biliary Obstruction</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lumen apposing metal stent (LAMS)</intervention_name>
    <description>Stent positioning</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective analysis of a prospectively maintained database of all consecutive patients&#xD;
        with distal malignat biliary obstruction, high surgical risk acute cholecystitis, or&#xD;
        symptomatic pancreatic fluid collection that underwent EUS drainage from January 2016 to&#xD;
        December 2022. All EUS drainage were performed by experienced operators.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  Patients with distal malignant common bile duct obstruction with failed ERCP&#xD;
&#xD;
          -  Patients with symptomatic peripancreatic fluid collections&#xD;
&#xD;
          -  Patients with acute cholecystitis who are unfit for surgery&#xD;
&#xD;
          -  Agree to receive follow up phone calls&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulation and/or platelets hereditary disorders.&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Inability to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Anderloni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Anderloni, MD</last_name>
    <phone>0039-02-82247308</phone>
    <email>andrea.anderloni@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Fugazza, MD</last_name>
    <phone>0039-02-82247021</phone>
    <email>alessandro.fugazza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Carrara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Anderloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Di Leo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Anderloni, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

